Randomized trial examines metabolic hormones' role in depression severity and early-life adversity in patients.
Key Points
This study aims to characterize metabolic hormone and adipokine profiles in patients with major depressive disorder and their association with depression severity and early-life adversity.
Characterized metabolic hormone and adipokine profiles in 125 MDD inpatients and 40 healthy controls.
Measured fasting serum levels of hormonal markers and assessed acute-phase inflammatory response.
Utilized correlation, regression analyses, and ROC-AUC to evaluate associations and discriminative performance.
MDD patients demonstrated significantly lower insulin, glucagon, and PAI-1 levels compared to controls.
A composite GAP index correlated negatively with depression severity, suicidal ideation, and adverse childhood experiences.
A model combining GAP index, inflammatory markers, and childhood adversity achieved an AUC of 0.864, indicating 80% accuracy in distinguishing MDD from controls.